Curative Effect Of Levetiracctam On Diagnosed Adult Patients With Epilepsy

ObjectiveLevetiracetam (levetiracetam, LEV) is a kind of new antiepileptic drugs(AEDs), a unique anti epilepsy mechanism. In1999, the product won FDAapproval for the treatment American, add epilepsy adult part, in2005the EUapproved epilepsy levetiracetam monotherapy with or without secondarygeneral seizure over the age of16newly diagnosed partial epilepsy.2007March, approved in China market, add on therapy for adult and children overthe age of4epileptic patients with partial seizures. This paper mainly studiesthe levetiracetam (LEV) clinical efficacy and safety of adding and singleagent in the treatment of adult epilepsy.MethodsA total of the study included147adult patients with epilepsy patients,including102cases previously diagnosed epileptic patients, who were taking1or more than1kinds of first-line antiepileptic drugs, failed to fully control,to add LEV treatment.45cases of newly diagnosed untreated various types ofadult epilepsy patients, treated with LEV monotherapy. And24week openand self controlled follow-up study, observe the effect and safety of treatment.ResultsAfter24weeks of treatment, LEV add on therapy of epileptic seizures inpatients with complete control rate was19.6%, the total efficiency of79.4%;simple partial seizure group, completely controlled in4cases (15.4%),12cases (46.2%), effective in5cases (19.2%), invalid5cases (19.2%); complex partial seizure group, was completely controlled in5cases (17.9%),10cases(35.7%), effective in9cases (32.1%), invalid4cases (14.3%); secondarygeneralized seizures group, completely controlled in8cases (25.8%),9cases(29%), effective in6cases (19.4%), invalid8cases (25.8%), a comprehensiveattack group, was completely controlled in3cases (17.6%),6cases (35.3%),effective in4cases (23.5%), invalid4cases (23.5%). There was no significantdifference between4groups.45cases of LEV monotherapy for epilepticseizures in patients with complete control rate was20%, the total efficiency of86.7%. Partial seizure group, was completely controlled in5cases (23.8%),effective in7cases (33.3%), effective in6cases (28.6%), invalid2cases(9.5%), increased in1cases (4.8%); total seizure group cases, completelycontrolled in4cases (16.7%),9cases (37.5%), effective in8cases (33.3%),invalid2cases (8.3%), increased in1cases (4.2%). There was no significantdifference between2groups. The use of levetiracetam after6-12months oftreatment were checked EEG,12cases (8.2%) of patients with epilepticdischarge disappeared,71cases (48.3%) EEG epileptiform dischargedecreased more than50%,64cases (43.5%) EEG improvement is not obvious,no EEG aggravating, remission rate of56.5%. The26.5%period oflevetiracetam therapy (39/147) in patients with adverse reaction. Adversereactions include sleepiness fatigue, dizziness, nausea and vomiting, loss ofappetite, no special treatment, after2-8weeks to ease, no cases because ofsevere adverse reactions and exit.Conclusion1.Levetiracetam add and monotherapy on various attack effect are typesof adult epilepsy.2. Levetiracetam add and single agent in the treatment of Adult EpilepsyEEG epileptiform discharge reduction greater than50%. 3.Levetiracetam add and single drug therapy with low incidence ofadverse reactions of adult epilepsy, short duration, and were tolerable degree.